It’s not just New York prioritizing non-white residents for COVID-19 treatments, Utah and Minnesota are also doing it.
As The Washington Free Beacon reported, the scheme didn’t start at state-level health departments, it began with the Food and Drug Administration (FDA).
“In New York, racial minorities are automatically eligible for scarce COVID-19 therapeutics, regardless of age or underlying conditions. In Utah, ‘Latinx ethnicity’ counts for more points than ‘congestive heart failure’ in a patient’s ‘COVID-19 risk score’—the state’s framework for allocating monoclonal antibodies. And in Minnesota, health officials have devised their own ‘ethical framework’ that prioritizes black 18-year-olds over white 64-year-olds—even though the latter are at much higher risk of severe disease,” the Free Beacon reported.
The racial discrimination stems from the FDA’s guidance when authorizing monoclonal antibodies